CNBX Pharmaceuticals is a clinical-stage biotech developing cannabinoid-based drug candidates for cancer treatment. CNBX's two lead programs are Cannabics SR, a sustained-release oral capsule targeting Cancer Anorexia-Cachexia Syndrome (CACS — a condition in advanced cancer patients marked by severe weight loss and muscle wasting), and RCC-33, an oral capsule combining two cannabinoids (CBDV and CBGA) for colorectal cancer treatment. Both are pre-Phase I and pre-revenue. CNBX also has four earlier-stage programs targeting colorectal polyps, breast cancer, melanoma, and prostate cancer. The company's business model is to advance its candidates through Phase I/II proof-of-concept trials, then license or partner them to larger pharma companies for commercialization — CNBX has no plans to build its own manufacturing or commercial infrastructure. All R&D is conducted through an Israeli subsidiary and outsourced where possible. CNBX has a single employee (its CEO) and needs to raise approximately $6.5M to fund its planned clinical trials, which are targeted for 2026. The company's entire value rests on its IP and the clinical data it can generate.